Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

New Feature: Text Message Treatment Updates

New to the Arfinn Med portal comes the ability to receive real time updates from patients via text messaging. This new addition will allow physicians to stay up to date on current patient efficacies as well as streamline the data collection process. Through the new text messaging function, physicians are able to send patients automated…
Read More →

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More →

World Cancer Day – Shine a Light on the World

In 2018, it was estimated that 1,735,350 new cancer cases would be diagnosed in the United States and 609,640 individuals would pass from the disease [Cancer.gov]. We cannot sit by and ignore this life altering disease, which is why World Cancer Day, recognized on Feb. 4, is such an important awareness campaign to the Arfinn…
Read More →

Cannabis for Treating IBD: Hope or Hype?

Nausea, abdominal pain and changes in appetite. These are all things that can significantly impact one’s wellbeing if left untreated, yet they have all shown marked improvements when associated with cannabis. Yet, less is known about the effects of cannabis on inflammatory bowel disease, or IBD, a chronic inflammatory condition that impacts the gastrointestinal tract…
Read More →

Arfinn Med Patient Site

We get a lot of interest from patients asking about efficacy data for medical marijuana on a number of conditions. Though we are primarily an electronic medical record (EMR) company focussing on the cannabis industry and other complimentary or alternative therapies, our primary focus is better quality care for patients. So with that being said,…
Read More →

Medical Marijuana a Hit With Seniors

In a new survey, those who turned to it for treating chronic pain reported it reduced pain and decreased the need for opioid painkillers. Nine out of 10 liked it so much they said they’d recommend medical pot to others. “I was on Percocet and replaced it with medical marijuana. Thank you, thank you, thank you,” said one senior. Another patient put…
Read More →

Leave a Comment

You must be logged in to post a comment.